![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Hetero Labs Limited Hyderabad In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Valsartan, Process-II, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2012-296 - Rev 02
This Chemical Type CEP, issued on August 10, 2017, remains in force until May 25, 2018, ensuring its reliability within the pharmaceutical industry.
Substance Number 2423 associated with this CEP further emphasizes